May 29, 2017 12:41 PM ET

Life Sciences Tools and Services

Company Overview of Crown Bioscience, Inc.

Company Overview

Crown Bioscience, Inc., a preclinical CRO, provides drug discovery and development services to biotech and pharmaceutical partners focusing on oncology and metabolic disease therapeutic areas. The company’s proprietary HuPrime, HuKemia, HuBase, HuMark, HuTrial, and HuSignature platforms enable lead optimization and translational strategies to deliver clinical candidates. It offers oncology services, such as oncology databases, Ex vivo services, human surrogate trials, in vitro and in vivo services, preclinical formulations, translational research, and drug discovery services; and metabolic disease services, including in vivo and in vitro services, cardiovascular and metabolic disease (CVMD) ...

3375 Scott Boulevard

Suite 108

Santa Clara, CA 95054

United States

Founded in 2006

Phone:

855-827-6968

Fax:

888-882-4881

Key Executives for Crown Bioscience, Inc.

Chief Executive Officer
Co-Founder, President and Chief Strategy Officer
Age: 52
Chief Financial Officer
Age: 58
Chief Operating Officer
Age: 51
President of International Institute of Biomedical Research (IIBR) & SVP of CVMD
Compensation as of Fiscal Year 2016.

Crown Bioscience, Inc. Key Developments

Crown Bioscience Announces Earnings Results for the First Quarter of 2017; Provides Earnings Guidance for the Full Year 2017

Crown Bioscience announced earnings results for the first quarter of 2017. For the quarter, the company's revenue reached TWD 493 million, a 34% YOY (year-over-year) growth. Gross margin reached 49.3% with EPS (earnings per share) of TWD 0.13. With the strong demand for Oncology and Immunology therapy, the company anticipates sustained revenue growth and increased profitability through 2017.

Crown Bioscience Announces Collaboration with Jiangsu Qyun Bio-Pharmaceutical Co. Ltd

Crown Bioscience announced a collaboration to develop a CTLA-4 antibody with Jiangsu Qyun Bio-Pharmaceutical Co. Ltd. As part of the collaboration agreement CrownBio will leverage Jiangsu Qyun Bio-Pharmaceuticals expertise to support the Investigational New Drug Application (IND) and further clinical development of CrownBio's proprietary 10B10 antibody. The collaboration agreement between CrownBio and Jiangsu Qyun Bio-Pharmaceutical Co. Ltd. is indicative of focus on innovation, and enhances portfolio in immuno-oncology. Moreover, this partnership highlights CrownBio's commitment to develop therapies that could significantly impact the way cancer is treated.

CrownBio Presents at Annual China Healthcare Investment Conference, Mar-29-2017 09:30 AM

CrownBio Presents at Annual China Healthcare Investment Conference, Mar-29-2017 09:30 AM. Venue: Shangri-La Pudong Hotel, Shanghai, China. Speakers: Qian Shi, VP, Oncology.

Similar Private Companies By Industry

Company Name Region
10X Genomics, Inc. United States
4G Clinical, Inc. United States
AAPharmaSyn LLC United States
Abiant, Inc. United States
aBioBot, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
The Advertising Council, Inc. United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Crown Bioscience, Inc., please visit www.crownbio.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.